Christopher L. Averill

Christopher L. Averill

Auto-generated profile, based on publicly available information

Christopher L. Averill

National Center for PTSD – Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
CAChadi G Abdallah
Chadi G Abdallah
LALynnette A Averill
Lynnette A Averill
KCKatherine A Collins
Katherine A Collins
PGPaul Geha
Paul Geha
JSJaclyn Schwartz
Jaclyn Schwartz
James W. MurroughJames W. Murrough
James W. Murrough

28 June 2018 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
CAChadi G. Abdallah
Chadi G. Abdallah
HFHenk M. De Feyter
Henk M. De Feyter
LALynnette A. Averill
Lynnette A. Averill
LJLihong Jiang
Lihong Jiang
CAChristopher L. Averill
Christopher L. Averill
GMGraeme F. Mason
Graeme F. Mason
The ability of ketamine administration to activate prefrontal glutamate neurotransmission is thought to be a key mechanism contributing to its transient psychotomimetic effects and its delayed and sustained antidepressant effects. Rodent studies employing carbon-13 magnetic resonance spectroscopy (13C MRS) methods have shown ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists to transiently increase measures reflecting glutamate–glutamine cycling and glutamate neurotransmission in the frontal cortex. However, there are not yet direct measures of glutamate neurotransmission in vivo in humans to support these hypotheses. The current first-level pilot study employed a novel prefrontal 13C MRS approach similar to that used in the rodent studies for direct measurement of ketamine effects on glutamate–glutamine cycling. Twenty-one participants (14 healthy and 7 depressed) completed two 13C MRS scans during infusion of normal saline or subanesthetic doses of ketamine. Compared to placebo, ketamine increased prefrontal glutamate–glutamine cycling, as indicated by a 13% increase in 13C glutamine enrichment (t = 2.4, p = 0.02). We found no evidence of ketamine effects on oxidative energy production, as reflected by 13C glutamate enrichment. During ketamine infusion, the ratio of 13C glutamate/glutamine enrichments, a putative measure of neurotransmission strength, was correlated with the Clinician-Administered Dissociative States Scale (r = −0.54, p = 0.048). These findings provide the most direct evidence in humans to date that ketamine increases glutamate release in the prefrontal cortex, a mechanism previously linked to schizophrenia pathophysiology and implicated in the induction of rapid antidepressant effects.

1 May 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
LALynnette A. Averill
Lynnette A. Averill
PPPrerana Purohit
Prerana Purohit
CAChristopher L. Averill
Christopher L. Averill
MBMarkus A. Boesl
Markus A. Boesl
JKJohn H. Krystal
John H. Krystal
CAChadi G. Abdallah
Chadi G. Abdallah

4 May 2016 in Human Brain Mapping
Verified
Journal Article
Open access
PDF file
James W. MurroughJames W. Murrough
James W. Murrough
CAChadi G. Abdallah
Chadi G. Abdallah
AAAlan Anticevic
Alan Anticevic
KCKatherine A. Collins
Katherine A. Collins
PGPaul Geha
Paul Geha
DCDennis S. Charney
Dennis S. Charney
Background: Major depressive disorder is a disabling neuropsychiatric condition that is associated with disrupted functional connectivity across brain networks. The precise nature of altered connectivity, however, remains incompletely understood. The current study was designed to examine the coherence of large‐scale connectivity in depression using a recently developed technique termed global brain connectivity. Methods: A total of 82 subjects, including medication‐free patients with major depression (n = 57) and healthy volunteers (n = 25) underwent functional magnetic resonance imaging with resting data acquisition for functional connectivity analysis. Global brain connectivity was computed as the mean of each voxel's time series correlation with every other voxel and compared between study groups. Relationships between global connectivity and depressive symptom severity measured using the Montgomery‐Åsberg Depression Rating Scale were examined by means of linear correlation. Results: Relative to the healthy group, patients with depression evidenced reduced global connectivity bilaterally within multiple regions of medial and lateral prefrontal cortex. The largest between‐group difference was observed within the right subgenual anterior cingulate cortex, extending into ventromedial prefrontal cortex bilaterally (Hedges' g = −1.48, P < 0.000001). Within the depressed group, patients with the lowest connectivity evidenced the highest symptom severity within ventromedial prefrontal cortex (r = −0.47, P = 0.0005). Conclusions: Patients with major depressive evidenced abnormal large‐scale functional coherence in the brain that was centered within the subgenual cingulate cortex, and medial prefrontal cortex more broadly. These data extend prior studies of connectivity in depression and demonstrate that functional disconnection of the medial prefrontal cortex is a key pathological feature of the disorder. Hum Brain Mapp 37:3214–3223, 2016. © 2016 Wiley Periodicals, Inc.

14 December 2021 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
ACAshley Clausen
Ashley Clausen
KFKelene A. Fercho
Kelene A. Fercho
MMMolly Monsour
Molly Monsour
SDSeth Disner
Seth Disner
LSLauren Salminen
Lauren Salminen
RMRajendra A. Morey
Rajendra A. Morey
Background: Posttraumatic stress disorder (PTSD) is associated with markers of accelerated aging. Estimates of brain age, compared to chronological age, may clarify the effects of PTSD on the brain and may inform treatment approaches targeting the neurobiology of aging in the context of PTSD.Method: Adult subjects (N = 2229; 56.2% male) aged 18–69 years (mean = 35.6, SD = 11.0) from 21 ENIGMA‐PGC PTSD sites underwent T1‐weighted brain structural magnetic resonance imaging, and PTSD assessment (PTSD+, n = 884). Previously trained voxel‐wise (brainageR) and region‐of‐interest (BARACUS and PHOTON) machine learning pipelines were compared in a subset of control subjects (n = 386). Linear mixed effects models were conducted in the full sample (those with and without PTSD) to examine the effect of PTSD on brain predicted age difference (brain PAD; brain age − chronological age) controlling for chronological age, sex, and scan site.Results: BrainageR most accurately predicted brain age in a subset (n = 386) of controls (brainageR: ICC = 0.71, R = 0.72, MAE = 5.68; PHOTON: ICC = 0.61, R = 0.62, MAE = 6.37; BARACUS: ICC = 0.47, R = 0.64, MAE = 8.80). Using brainageR, a three‐way interaction revealed that young males with PTSD exhibited higher brain PAD relative to male controls in young and old age groups; old males with PTSD exhibited lower brain PAD compared to male controls of all ages.Discussion: Differential impact of PTSD on brain PAD in younger versus older males may indicate a critical window when PTSD impacts brain aging, followed by age‐related brain changes that are consonant with individuals without PTSD. Future longitudinal research is warranted to understand how PTSD impacts brain aging across the lifespan.

1 January 2018 in Chronic Stress
Verified
Journal Article
Open access
PDF file
CAChadi G. Abdallah
Chadi G. Abdallah
ADArpan Dutta
Arpan Dutta
CAChristopher L. Averill
Christopher L. Averill
SMShane McKie
Shane McKie
TATeddy J. Akiki
Teddy J. Akiki
JDJ. F. William Deakin
J. F. William Deakin
Identifying the neural correlates of ketamine treatment may facilitate and expedite the development of novel, robust, and safe rapid-acting antidepressants. Prefrontal cortex (PFC) global brain connectivity with global signal regression (GBCr) was recently identified as a putative biomarker of major depressive disorder. Accumulating evidence have repeatedly shown reduced PFC GBCr in major depressive disorder, an abnormality that appears to normalize following ketamine treatment. Fifty-six unmedicated participants with major depressive disorder were randomized to intravenous placebo (normal saline; n = 18), ketamine (0.5 mg/kg; n = 19), or lanicemine (100 mg; n = 19). PFC GBCr was computed using time series from functional magnetic resonance imaging scans that were completed at baseline, during infusion, and at 24-h posttreatment. Compared to placebo, ketamine significantly increased average PFC GBCr during infusion (p = 0.01) and at 24-h posttreatment (p = 0.02). Lanicemine had no significant effects on GBCr during infusion (p = 0.45) and at 24-h posttreatment (p = 0.23) compared to placebo. Average delta PFC GBCr (during minus baseline) showed a pattern of positively predicting depression improvement in participants receiving ketamine (r = 0.44; p = 0.06; d = 1.0) or lanicemine (r = 0.55; p = 0.01; d = 1.3) but not those receiving placebo (r = −0.1; p = 0.69; d = 0.02). Follow-up vertex-wise analyses showed ketamine-induced GBCr increases in the dorsolateral, dorsomedial, and frontomedial PFC during infusion and in the dorsolateral and dorsomedial PFC at 24-h posttreatment (corrected p < 0.05). Exploratory vertex-wise analyses examining the relationship with depression improvement showed positive correlation with GBCr in the dorsal PFC during infusion and at 24-h posttreatment but negative correlation with GBCr in the ventral PFC during infusion (uncorrected p < 0.01). In a randomized placebo-controlled approach, the results provide the first evidence in major depressive disorder of ketamine-induced increases in PFC GBCr during infusion and suggest that ketamine’s rapid-acting antidepressant properties are related to its acute effects on prefrontal connectivity. Overall, the study findings underscore the similarity and differences between ketamine and another N-methyl-D-aspartate receptor antagonist while proposing a pharmacoimaging paradigm for the optimization of novel rapid-acting antidepressants prior to testing in costly clinical trials.